7.4.3. intravesical bacillus calmette-guérin (bcg) immunotherapy. 7.4.3.1. efficacy bcg 7.4.3.1.1. recurrence rate five meta-analyses confirmed bcg turb superior turb alone turb plus chemotherapy preventing recurrence nmibc [285,307-310]. three rcts intermediate- high-risk tumours compared bcg epirubicin interferon (inf) , mmc , epirubicin alone confirmed superiority bcg prevention tumour recurrence (le: 1a). effect long lasting also observed separate analysis patients intermediate-risk tumours . one meta-analysis evaluated individual data 2,820 patients enrolled 9 rcts compared mmc vs. bcg. trials bcg maintenance, 32% reduction risk recurrence bcg compared mmc, 28% increase risk recurrence patients treated bcg trials without bcg maintenance. cochrane systematic review confirmed bcg effective reducing recurrence rate mmc . 7.4.3.1.2. progression rate two meta-analyses demonstrated bcg therapy delays potentially lowers risk tumour progression (le: 1a). meta-analysis carried eortc gucg evaluated data 4,863 patients enrolled 24 rcts. 20 trials, form bcg maintenance used. based median follow-up 2.5 years, tumours progressed 9.8% patients treated bcg compared 13.8% control groups (turb alone, turb intravesical chemotherapy, turb addition immunotherapy). shows reduction 27% odds progression bcg maintenance treatment. size reduction similar patients tat1 papillary tumours cis . rct long-term follow-up demonstrated significantly fewer distant metastases better overall- disease-specific survival patients treated bcg compared epirubicin (le: 1b). contrast, individual patient data meta-analysis cochrane review able confirm statistically significant difference mmc bcg progression, survival, cause death . conflicting results outcomes studies explained different patient characteristics, duration follow-up, methodology statistical power. however, studies showed reduction risk progression high-and intermediate-risk tumours bcg maintenance schedule applied. 7.4.3.1.3. influence factors two meta-analyses suggested possible bias favour bcg arising inclusion patients previously treated intravesical chemotherapy . individual patient data meta-analysis, however, bcg maintenance effective mmc reduction recurrence rate, patients previously treated previously treated chemotherapy (le: 1a). demonstrated bcg less effective patients > 70 years age, still effective epirubicin cohort elderly patients (le: 1a). according cohort analysis, risk tumour recurrence bcg shown higher patients previous history utuc . 7.4.3.2. bcg strain although smaller studies without maintenance demonstrated differences strains [316-318], network meta-analysis identified ten different bcg strains used intravesical treatment published literature able confirm superiority bcg strain another . similarly, meta-analysis prospective rcts , published data prospective registry well post-hoc analysis large phase ii prospective trial assessing bcg inf-α bcg-naive bcg-failure patients suggest clear difference efficacy different bcg strains . quality data, however, allow definitive conclusions. 7.4.3.3. bcg toxicity bacillus calmette-guérin intravesical treatment associated side effects compared intravesical chemotherapy . however, serious side effects encountered < 5% patients treated effectively almost cases . incidence bcg infections bcg instillations 1% registry-based cohort analysis . shown maintenance schedule associated increased risk side effects compared induction course . side effects requiring treatment stoppage seen often first year therapy . elderly patients seem experience side effects leading treatment discontinuation . significant difference toxicity different bcg strains demonstrated . symptoms may result side effects bcg treatment caused bladder disease (widespread cis) itself. consequently, burden symptoms reduced completion treatment significant number patients albeit delayed hypersensitivity bcg may rarely present even years completion treatment . major complications appear systemic absorption drug. thus, contraindications bcg intravesical instillation respected (see section 7.9). presence leukocyturia, nonvisible haematuria asymptomatic bacteriuria contraindication bcg application, antibiotic prophylaxis necessary cases (le: 3). three rcts showed reduced side effects administering different quinolones conjunction bcg-instillations [328-330]. latter, using two doses levofloxacin (at 6 12 hours first voiding) conjunction bcg-instillation, reduced proportion patients high-grade side effects, local (pollakisuria) systemic (fever), without improving completion rate maintenance regimen risk severe bcg related adverse events . bacillus calmette-guérin used caution immunocompromised patients. immunosuppression, example human immunodeficiency virus (hiv) infection, poses relative contraindications , although small studies shown similar efficacy increase complications compared non-immunocompromised patients. role prophylactic anti-tuberculosis medication patients remains unclear [332-334]. kidney transplant recipients safely treated bcg . management side effects bcg reflect type grade according recommendations provided international bladder cancer group (ibcg) spanish group (table 7.1). table 7.1: management options side effects associated intravesical bcg [337-340] management options local side effects (modified international bladder cancer group)symptoms cystitisphenazopyridine, propantheline bromide, non-steroidal anti-inflammatory drugs (nsaids).if symptoms improve within days: continue instillations.if symptoms persist worsen:a.postpone instillation.b.perform urine culture.c.start empirical antibiotic treatment.if symptoms persist even antibiotic treatment:a.with positive culture: adjust antibiotic treatment according sensitivity.b.with negative culture: quinolones* potentially analgesic anti-inflammatory instillations daily 5 days (repeat cycle necessary) .if symptoms persist: anti-tuberculosis drugs + corticosteroids.if response treatment and/or contracted bladder: radical cystectomy.haematuriaperform urine culture exclude haemorrhagic cystitis symptoms present.if haematuria persists, perform cystoscopy evaluate presence bladder tumour.symptomatic granulomatousprostatitissymptoms rarely present: perform urine culture.quinolones.if quinolones effective: isoniazid (300 mg/day) rifampicin (600 mg/day) 3 months.cessation intravesical therapy.epididymo-orchitis perform urine culture administer quinolones.cessation intravesical therapy.orchidectomy abscess response treatment.management options systemic side effectsgeneral malaise, fevergenerally resolve within 48 hours, without antipyretics.arthralgia and/or arthritisrare complication considered autoimmune reaction.arthralgia: treatment nsaids.reactive arthritis: nsaids.if no/partial response, proceed corticosteroids, high-dose quinolones antituberculosis drugs .persistent high-grade fever(> 38.5°c > 48 h)permanent discontinuation bcg instillations.immediate evaluation: urine culture, blood tests, chest x-ray.prompt treatment two antimicrobial agents diagnostic evaluation conducted.consultation infectious diseases specialist.bcg sepsisprevention: initiate bcg least 2 weeks post-transurethral resection bladder (if signs symptoms haematuria).cessation bcg.for severe infection:high-dose quinolones isoniazid, rifampicin, ethambutol 1.2 g daily for6 months.early, high-dose corticosteroids long symptoms persist.consider empirical non-specific antibiotic cover gram-negative bacteria and/or enterococcus.allergic reactionsantihistamines anti-inflammatory agents.consider high-dose quinolones isoniazid rifampicin persistent symptoms.delay therapy reactions resolve. * persistent severe cystitis symptoms associated bcg use high risk underlie complicated uti (even absence positive culture) thus restriction applies empirical use quinolones pharmacovigilance risk assessment committee ema (see also section 3.7 complicated uti 3.7.4.1- choice antimicrobials eau guidelines urological infection 2022). [341, 342] 7.4.3.4. optimal bcg schedule induction bcg instillations given according empirical 6-weekly schedule introduced morales et al., . optimal efficacy, bcg must given maintenance schedule [283-285,310]. many different maintenance schedules used, ranging total 10 instillations given 18 27 weeks 3 years . optimal 3-years maintenance schedule outlined recommendation table 7.10. 7.4.3.4.1. optimal number induction instillations frequency instillations maintenance optimal number induction instillations frequency maintenance instillations evaluated nimbus, prospective phase iii rct. safety analysis 345 randomised patients demonstrated reduced number instillations (3 instillations induction 2 instillations 3, 6 12 months) proved inferior standard schedule (6 instillation induction 3 instillations 3, 6 12 months) regarding time first recurrence . rct including 397 patients cueto showed high-risk tumours maintenance schedule one instillation every 3 months 3 years superior induction therapy only, suggested one instillation may suboptimal 3 instillations maintenance cycle . 7.4.3.4.2. optimal length maintenance meta-analysis, böhle et al., concluded least one year maintenance bcg required obtain superiority bcg mmc prevention recurrence progression . rct 1,355 patients, eortc shown bcg given full dose, 3 years’ maintenance (3-weekly instillations 3, 6, 12, 18, 24, 30 36 months) reduces recurrence rate compared one year high- intermediate-risk patients. differences progression os. 3-year arm, however, 36.1% patients complete 3-year schedule . main reason patients stopped treatment treatment inefficacy, toxicity. 7.4.3.5. optimal dose bcg reduce bcg toxicity, instillation reduced dose proposed. however, suggested full dose bcg effective multifocal tumours . cueto study compared one-third dose full-dose bcg found overall difference efficacy. one-third standard dose bcg might minimum effective dose intermediate-risk tumours. reduction one-sixth dose resulted decrease efficacy decrease toxicity . eortc find difference toxicity one-third full-dose bcg, one-third dose bcg associated higher recurrence rate, especially given one year . recent meta-analysis 9 rcts, patients received less half standard bcg dose experienced less adverse events compared patients receiving full dose, faced unfavourable outcomes higher rates disease recurrences . 7.4.3.6. bcg shortage statement panel bcg shortage accessed online:https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/publications-appendices. 7.4.3.7. summary evidence - bcg treatment summary evidencelein patients intermediate- high-risk tumours, intravesical bcg turb reduces risk tumour recurrence; effective turb alone turb intravesical chemotherapy.1afor optimal efficacy, bcg must given maintenance schedule. complete bcg schedule comprises induction phase 6-weekly instillations, followed maintenance phase three-weekly instillations 3, 6, 12, 18, 24, 30 36 months, respectively.1athree-year maintenance effective one year prevent recurrence patients high-risk tumours, patients intermediate-risk tumours.1a